IO Biotech, Inc. IOBTQ
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $3.5M
- P/E
- 0.0×
Follow IOBTQ
| Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
3.33 | 9.37 | 13.88 | 21.52 | 1.85 | 0.87 | — |
Net Debt/EBITDA |
0.63 | 1.57 | 2.00 | 5.13 | 0.34 | (0.08) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 91.93% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (5.89) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.86 | 0.83 | 0.84 | 0.54 | 0.68 | 0.71 | — |
Capex/Depreciation |
(0.17) | (1.50) | (6.63) | (76.50) | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (106.00%) | (63.29%) | (40.74%) | (84.91%) | 49.61% | 42.55% | — | |
| (87.44%) | (56.91%) | (38.20%) | (65.80%) | (193.61%) | (265.67%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | (6,557.57%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(207.13%) | (65.02%) | (51.67%) | (35.44%) | (564.56%) | 869.84% | — |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(1.25) | (1.65) | (2.10) | (9.41) | (56.19) | (0.31) | — |
Cash per Share |
0.91 | 3.29 | 4.95 | 48.78 | 19.22 | 0.27 | — |
Shareholders Equity per Share |
0.71 | 3.06 | 4.82 | 48.88 | (199.23) | (0.05) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.71 | 3.06 | 4.82 | 48.88 | (199.23) | (0.05) | — |
Free Cash Flow |
(82.39) | (72.06) | (60.42) | (40.80) | (9.96) | (8.89) | — |
Working Capital |
45.47 | 131.54 | 137.54 | 211.43 | 2.59 | (1.44) | — |
Capital Expenditures |
(0.04) | (0.32) | (0.69) | (0.15) | — | — | — |
Net Current Asset Value |
44.27 | 129.70 | 135.27 | 211.37 | (35.32) | (1.49) | — |
| Other line items | |||||||
Quick Ratio |
3.08 | 9.11 | 13.36 | 20.53 | 1.12 | 0.84 | — |
Depreciation/Fixed assets |
0.40 | 0.25 | 0.14 | 0.01 | — | — | — |
Cash ROIC |
(77.52%) | (26.26%) | (21.49%) | (9.64%) | 31.21% | (59.12%) | — |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | 0.00 | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.25) | (1.65) | (2.07) | (9.37) | (56.19) | (0.31) | — |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.04) | 0.00 | 0.00 | — |
Average Receivables |
— | — | 1.81 | 1.80 | 1.37 | 1.37 | — |
Average Payables |
4.27 | 3.94 | 3.97 | 2.23 | 0.76 | 0.76 | — |
Average Assets |
109.21 | 151.26 | 187.05 | 113.97 | 7.54 | 4.71 | — |
Average Common Equity |
90.09 | 136.01 | 175.39 | 88.31 | (29.42) | (29.42) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates